Trials / Completed
CompletedNCT04065932
A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets
A Study to Determine the Pharmacokinetic Profile of BMS-986165 Administered as Various Solid Dispersion Tablet Formulations in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A Study to Determine the Drug Level Profile of Different formulations of BMS-986165 Tablets
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986165-01 | Participants will receive BMS- 986165 -01 in prototype formulation |
| DRUG | BMS-986165 Tablet | Participants will receive BMS-986165 in tablet form. |
| DRUG | Famotidine | Participants will receive a previously dosed BMS-985165-01 Prototype Tablet at the same dose level following administration of famotidine |
Timeline
- Start date
- 2019-08-22
- Primary completion
- 2019-12-08
- Completion
- 2019-12-10
- First posted
- 2019-08-22
- Last updated
- 2021-01-06
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04065932. Inclusion in this directory is not an endorsement.